Absence of Clinically Meaningful Drug-Drug Interactions with Rezafungin: Outcome of Investigations
Shawn D. Flanagan, Helen Walker, Voon Ong, Taylor Sandison
Abstract
Antifungal agents used to treat life-threatening infections are often associated with severe drug-drug interactions (DDIs) that may limit their usefulness. Rezafungin, a newly approved once-weekly echinocandin, has been shown to be free of DDIs based on extensive nonclinical and clinical testing described in this study.
Topics & Concepts
DrugOutcome (game theory)Drug-drug interactionMedicinePharmacologyMathematicsMathematical economicsAntifungal resistance and susceptibilityFungal Infections and StudiesPhenothiazines and Benzothiazines Synthesis and Activities